DBV, INRA win research grant to develop pediatric Respiratory Syncytial Virus vaccine
RSV-NanoViaSkin is being developed as a non-invasive and adjuvant-free epicutaneous RSV pediatric vaccine that leverages Viaskin technology. Viaskin technique, developed by DBV, enables epicutaneous application of the vaccine
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.